Help us: Donate
Follow us on:
×

Menu

Back

Tag: UNITY Biotechnology

Longevity Therapeutics banner
February 03, 2021
Like nearly all conferences this past year, the 3rd Annual Longevity Therapeutics Summit, presented by Hanson Wade Limited, went virtual this time around. This was a stark difference from the previous two, which were rather fancy affairs in downtown San Francisco. However, we were fortunate that the organizers went forward with the event, bringing together...
2021 on a stethoscope
January 15, 2021
The world of rejuvenation biotechnology is a rapidly changing and ever developing place. As with any disruptive technology, the challenges are significant and include not only the technical aspects of developing these technologies but also the hurdles of societal acceptance of the desirability of longer, healthier lives. While I do not accept the idea proposed...
Dr. Judith Campisi
December 07, 2020
At Ending Age-Related Diseases 2020, Prof. Judith Campisi of the Buck Institute for Research on Aging discussed the effects and usage of senolytics, drugs that remove senescent cells from the body. She went into the details of the stress and damage signals that cause cells to become senescent and the markers of senescent cells, noting...
Rejuvenation Roundup October
November 02, 2020
Spooky season has come and gone, but the Grim Reaper is still chasing us down. Fortunately, we've learned quite a bit over the last month in finding ways to stop Death from getting a hold of us quite so soon. LEAF News Based in the United Kingdom, the All Party Parliamentary Group (APPG) for Longevity...
October 13, 2020
Unity Biotechnology has recently announced the launch of its Phase 1 study of UBX1325 for patients with diabetic macular edema. The drug is designed to remove problematic senescent cells from the body which accumulate as we get older and are a reason we age. Cellular SenescenceAs your body ages, more of your cells become senescent....
August 18, 2020
While we enjoy reporting positive news, we do occasionally have to report bad news, and today is one of those days. There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY...